RDM1 promotes neuroblastoma growth through the RAS-Raf-MEK-ERK pathway

被引:6
|
作者
Xie, Guojin [1 ]
Wu, Haiyan [1 ]
Cai, Weiluo [2 ]
Chen, Mo [2 ]
Huang, Wending [2 ]
Yan, Wangjun [2 ]
Chang, Yong [1 ]
机构
[1] Nanjing Med Univ, Childrens Hosp, Guangzhou Rd, Nanjing 210011, Jiangsu, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Musculoskeletal Tumor, Dongan Rd, Shanghai 200032, Peoples R China
来源
FEBS OPEN BIO | 2019年 / 9卷 / 03期
基金
中国国家自然科学基金;
关键词
apoptosis; neuroblastoma; RAS-Raf-MEK-ERK pathway; RDM1; STRAND BREAK REPAIR; DNA; RECOMBINATION; ONCOGENE; MEK/ERK; GENE;
D O I
10.1002/2211-5463.12586
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neuroblastoma (NB) is an aggressive cancer that originates in the sympathetic nervous system and primarily affects children. Here, we show that high levels of RAD52 motif containing 1 (RDM1; a protein with similarities to RAD52, which is important for double-strand DNA repair) are associated with poor clinical outcomes for NB. In addition, RDM1(-/-) cells exhibited increased sensitivity to cisplatin, a common chemotherapy drug, and disruption of RDM1 suppressed NB cell proliferation. We also report that loss of RDM1 augmented cell apoptosis and induced cell cycle arrest, and that stable knockdown of RDM1 significantly inhibited NB tumor growth in a xenograft mouse model. Importantly, we identified that RDM1 promoted cell proliferation via the RAS-Raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling pathway. In conclusion, the current study demonstrates a correlation between DNA damage regulator RDM1 and the oncogenic RAS-Raf-MEK-ERK pathway in NB.
引用
收藏
页码:490 / 497
页数:8
相关论文
共 50 条
  • [1] The Ras-Raf-MEK-ERK pathway in the treatment of cancer
    Hilger, RA
    Scheulen, ME
    Strumberg, D
    ONKOLOGIE, 2002, 25 (06): : 511 - 518
  • [2] Prohibitins Role in Cellular Survival Through Ras-Raf-MEK-Erk Pathway
    Chowdhury, Indrajit
    Thompson, Winston E.
    Thomas, Kelwyn
    JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (08) : 998 - 1004
  • [3] Signaling through RAS-RAF-MEK-ERK: from basics to bedside
    Zebisch, Armin
    Czernilofsky, Armin P.
    Keri, Gyoergy
    Smigelskaite, Juja
    Sill, Heinz
    Troppmair, Jakob
    CURRENT MEDICINAL CHEMISTRY, 2007, 14 (05) : 601 - 623
  • [4] Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
    Avery, Thomas Yul
    Koehler, Natalie
    Zeiser, Robert
    Brummer, Tilman
    Ruess, Dietrich Alexander
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway
    Yang, Haifeng
    Wan, Zhenzhou
    Huang, Cheng
    Yin, Huabin
    Song, Dianwen
    LASERS IN MEDICAL SCIENCE, 2019, 34 (03) : 473 - 478
  • [6] KSR1 as a therapeutic target for hepatocellular carcinoma with activated RAS-RAF-MEK-ERK signaling pathway
    Moon, H.
    Park, H.
    Jun, M.
    Lee, S.
    Lee, S.
    Lee, J.
    Ro, S. W.
    ANNALS OF ONCOLOGY, 2024, 35 : S220 - S221
  • [7] AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway
    Haifeng Yang
    Zhenzhou Wan
    Cheng Huang
    Huabin Yin
    Dianwen Song
    Lasers in Medical Science, 2019, 34 : 473 - 478
  • [8] Tax1 Enhances Cancer Cell Proliferation via Ras-Raf-MEK-ERK Signaling Pathway
    Song, Chunjiao
    Wang, Weimin
    Li, Meng
    Liu, Yanxin
    Zheng, Dexian
    IUBMB LIFE, 2009, 61 (06) : 685 - 692
  • [9] Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway
    Rejane Paumelle
    David Tulashe
    Zoulika Kherrouche
    Serge Plaza
    Catherine Leroy
    Syline Reveneau
    Bernard Vandenbunder
    Veronique Fafeur
    Oncogene, 2002, 21 : 2309 - 2319
  • [10] Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway
    Paumelle, R
    Tulasne, D
    Kherrouche, Z
    Plaza, S
    Leroy, C
    Reveneau, S
    Vandenbunder, B
    Fafeur, V
    ONCOGENE, 2002, 21 (15) : 2309 - 2319